Friday 6 November 2026
Export EW’s income statement to Excel — free account
Edwards Lifesciences Corporation
Edwards Lifesciences Corporation’s revenue for fiscal 2025 (year ended December 2025) was $6.1 billion, up 11.5% from fiscal 2024.
- Revenue
- +10.5%
- EPS
- +6.00%
- Free cash flow
- −1.84%
- Total debt
- +0.10%
Quarter to September 2026, against a year earlier
101.78
0.96
+0.95%
Follow EW
Alert me
Edwards Lifesciences Corporation (EW) revenue by segment, product and region
Where the money comes from and where it goes
| United States | 3,543 | 58.39% |
|---|---|---|
| Europe | 1,518 | 25.01% |
| Rest of World | 652 | 10.75% |
| Japan | 355 | 5.85% |
| Gross margin | 78.01% | |
| Operating margin | 20.84% | |
| Pre-tax margin | 20.98% |
Revenue by product or service $m
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 | FY2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Transcatheter Aortic Valve Replacement | 4,488 73.96% | 4,106 75.49% | 3,880 77.44% | 3,518 78.81% | 3,423 65.41% | 2,857 65.14% | 2,738 62.97% | 2,284 61.35% | 2,024 58.91% | 1,629 54.95% | 1,180 47.33% | 944 40.62% | 708 34.60% | 552 29.06% | 334 19.89% | 206 14.26% | — | — |
| Surgical | 1,029 16.96% | 981 18.04% | 933 18.61% | 830 18.59% | 889 16.99% | 762 17.37% | 842 19.36% | 762 20.46% | 807 23.49% | 775 26.15% | 785 31.48% | 826 35.56% | 801 39.17% | 788 41.46% | 784 46.73% | 732 50.59% | — | — |
| Transcatheter Mitral and Tricuspid Therapies | 551 9.07% | 352 6.47% | 198 3.94% | 116 2.60% | 86 1.64% | 42 0.95% | 28 0.65% | 3 0.08% | 3 0.10% | — | — | — | — | — | — | — | — | — |
| Critical Care | — | — | — | — | 835 15.96% | 725 16.54% | 740 17.02% | 675 18.12% | 601 17.49% | 560 18.91% | 528 21.19% | 553 23.82% | 537 26.23% | 560 29.48% | 560 33.38% | 509 35.14% | 453 34.24% | 452 36.50% |
| Heart Valve Therapy | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 715 54.10% | 607 49.07% |
| Cardiac Surgery Systems | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 93 7.02% | 89 7.21% |
| Vascular | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 61 4.63% | 89 7.21% |
| Revenue | 6,068 | 5,440 | 5,010 | 4,464 | 5,233 | 4,386 | 4,348 | 3,723 | 3,435 | 2,964 | 2,494 | 2,323 | 2,046 | 1,900 | 1,679 | 1,447 | 1,321 | 1,238 |
Gross profit by product or service $m, and margin
Revenue by segment $m
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | 3,543 58.39% | 3,206 58.94% | 2,948 58.84% | 2,628 58.88% | 2,963 56.63% | 2,517 57.38% | 2,533 58.25% | 2,055 55.21% | 1,908 55.53% | 1,616 54.52% | 1,263 50.64% | 1,047 45.09% | 940 45.93% | 812 42.75% | 606 36.08% |
| Europe | 1,518 25.01% | 1,322 24.30% | 1,180 23.56% | 1,040 23.30% | 1,100 21.01% | 945 21.55% | 926 21.30% | 826 22.20% | 801 23.31% | 746 25.17% | 843 33.80% | 741 31.92% | 622 30.42% | 577 30.37% | 549 32.73% |
| Rest of World | 652 10.75% | 572 10.52% | 531 10.60% | 436 9.77% | 533 10.19% | 452 10.29% | 433 9.97% | 396 10.64% | 357 10.40% | 304 10.24% | 315 12.64% | 285 12.27% | 253 12.36% | 236 12.42% | 201 11.96% |
| Japan | 355 5.85% | 340 6.25% | 351 7.00% | 360 8.05% | 528 10.09% | 449 10.23% | 441 10.15% | 398 10.70% | 357 10.38% | 280 9.43% | 297 11.92% | 271 11.66% | 294 14.36% | 293 15.45% | 227 13.51% |
| Other, not broken out | — | — | — | — | 109 2.08% | 24 0.55% | — | 47 1.26% | — | 19 0.64% | — | — | — | — | 96 5.72% |
| Eliminations | — | — | — | — | — | — | — | — | — | — | (224) (9.00%) | (22) (0.93%) | (63) (3.07%) | (19) (0.99%) | — |
| Revenue | 6,068 | 5,440 | 5,010 | 4,464 | 5,233 | 4,386 | 4,348 | 3,723 | 3,435 | 2,964 | 2,494 | 2,323 | 2,046 | 1,900 | 1,679 |